Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.
This week, Medtronic presented data from two new real-world trials confirming that ICDs save lives; a restraining order was issued against EOFlow in Insulet’s intellectual property case; and Polarean’s MRI gas XENOVIEW received a new Medicare reimbursement code.
The majority of FDA’s circulatory systems devices panel agreed that ReCor’s Paradise ultrasound renal denervation system offers a safe and effective therapy for patients with hypertension. The panel’s endorsement means ReCor will likely be the first company to reach the US market with an RDN system.
FDA’s circulatory system advisory panel narrowly voted against Medtronic’s Symplicity Spyral, because one of the pivotal trials of the radiofrequency renal denervation system missed its primary endpoint and the patient population evaluated in the trial does not match the requested indication.
Withings receives FDA clearance for first body weight scale to detect atrial fibrillation.
News We’re Watching: Califf Talks ORA Reorg, Contaminants Bring Ventilator Recall, 27-Year Sentence On Medicare Fraud
This week, FDA Commissioner Robert Califf described plans for restructuring the Office of Regulatory Affairs; Studies found chatbots don’t give trustworthy advice to cancer patients; and the owner of an Atlanta genetic testing lab was sentenced to 27 years in prison over a massive Medicare fraud scheme.
Considering where and how a test will be used, and what kind of evidence regulators will want before clearing it, is key for developers of at home and point-of-care diagnostics.
Roche received FDA clearance for its Solo insulin patch pump, but is expected to face significant barriers to entry in the highly competitive US insulin pump market.
If the pace is maintained in the second half of the year, 2023 could see the most US device approvals in a decade.
News We’re Watching: ReCor And Medtronic Head To RND Panel, Clearances For Anika And Sequel, ZimVie And Brainlab Partner
This week, the US FDA geared up for a renal denervation panel meeting; a microbiology panel meeting was announced; and a hyaluronic acid patch to promote rotator cuff healing, a novel spiral tampon, and a tibial neuromodulation device to treat incontinence all won FDA clearance.
GE HealthCare’s newly FDA-cleared Portrait Mobile enables real-time continuous wireless monitoring of patient vital signs such as respiration rate.
Results of a study of FDA and CMS data found that 44% of 64 new devices were granted some kind of Medicare coverage within 5 years of FDA approval of clearance.
News We’re Watching: Boston Scientific's POLARx Is Approved, IABP Recalls, Intricon Opens Facility in Costa Rica
This week, FDA cleared Terumo's Reveos automated whole blood processing system, Abbott adds the Alinity-h hematology system to its comprehensive lab diagnostics lineup, Movano moves forward with "smart ring" technology, and more.
News We’re Watching: Medtronic Kickbacks Case, BARDA Contract For Cue, Imeka Neuroimaging Software Cleared
This week, a court ordered a Medtronic whistleblower to hand over records of his media contacts; Cue Health was awarded $28m to develop a multi-disease respiratory panel; and the FDA granted a zero fluoroscopy Indication to some Biosense Webster cardiac ablation devices.
Orthopedics Corner: Catalyst Looks To Clinical Data To Distinguish Its Shoulder Arthroplasty Technology
Orthopedics Corner is a new series highlighting new developments in spine and orthopedics technology you may have missed. Catalyst OrthoScience CEO Carl O’Connell, along with surgeon and researcher Matthew Budge, talked to Medtech Insight about Catalyst’s innovation in shoulder arthroplasty.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.